Top

Supportive Care in Cancer

Published in:

01-10-2007 | Short Communication

Screening for depressive symptoms in patients with unresectable lung cancer

Authors: S. Néron, J. A. Correa, E. Dajczman, G. Kasymjanova, H. Kreisman, D. Small

Published in: Supportive Care in Cancer | Issue 10/2007

Abstract

Introduction

Early identification of psychological distress and depression is important to optimise the quality of life in patients with advanced non-small cell lung cancer (NSCLC). The prevalence of depression may vary, depending on the time since diagnosis of cancer, results of the treatment and the prognosis. The purpose of this study was to compare the efficacy of a self-administered screening tool (Hospital Anxiety and Depression Scale (HADS)) with a health professional administered tool (Montgomery–Asberg Depression Rating Scale (MADRS)) and to explore the variability of major affective symptoms in patients with unresectable lung cancer during the initial 7–8 weeks of chemotherapy treatment for their illness.

Material and methods

Patients with newly diagnosed unresectable lung cancer were screened on four occasions for anxiety and depressive symptoms simultaneously using the self-rated HADS and the MADRS administered by a psycho-oncologist or a trained research associate. The first assessment was done within 1 week of diagnosis and was repeated on 3 occasions during the initial 2 cycles of chemotherapy.

Results

Forty-nine patients, aged 38–82 years (median age 63 years) were enrolled. All patients had advanced NSCLC (stages 3A, 3B and 4) and 61% (30 patients) had an ECOG performance status (PS) of 1 or greater. The point prevalence of depression measured by an interviewer using the MADRS at visits 1–4 was 49%, 51%, 47%, and 41%, respectively. The point prevalence of self-reported depression (HADS) was significantly (p < 0.001) lower at each assessment point (18%, 20%, 6%, 12%) compared to health professional detected depression (MADRS). Although MADRS and HADS showed very strong (Pearson’s correlation = 0.8) and significant (p < 0.001) correlation, the concordance rate in identifying the same cases of depression was only 54%.

Clinical implication and conclusion

The prevalence of depression among advanced lung cancer patients is high and varies very little during the first 2 cycles of chemotherapy. Among a variety of tools available for the screening of depression, a semi-structured interview is more effective at identifying clinically significant depression than a self-administered questionnaire.

Adkins B, Titus-Howard T, Massey V et al (2005) Recognizing depression in cancer outpatients. Community Oncology 2:528–533

Akechi T, Okuyama T, Akizuki N et al (2006) Course of psychological distress and its predictors in advanced non-small cell lung cancer patients. Psychooncology 15:463–473PubMedCrossRef

Ballenger JC, Davidson JR, Lecrubier Y et al (2001) Consensus statement on depression, anxiety and oncology. J Clin Psychiatry 62:64–67PubMed

Berard RMF, Boermeester F, Viljoen G (1998) Depressive disorders in an out-patient oncology setting: prevalence, assessment, and management. Psychooncology 7:112–120PubMedCrossRef

Bjelland I, Dahl AA, Haug TT et al (2002) The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 52:69–77PubMedCrossRef

Block SD (2000) Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 132:209–218PubMed

Carlsen K, Jensen AB, Jacobsen E et al (2005) Psychosocial aspects of lung cancer. Lung Cancer 47:293–300PubMedCrossRef

Carroll BT, Kathol RG, Noyes R Jr et al (1993) Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 15:69–74PubMedCrossRef

Chochinov HM (2001) Depression in cancer patients. Lancet Oncol 2:499–505PubMedCrossRef

10.

Donaldson G, Moinpour CM (2005) Learning to live with missing quality-of-life data in advanced-stage disease trials. J Clin Oncol 23:7380–7384PubMedCrossRef

11.

Derogatis LR, Morrow GR, Fetting J et al (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249:751–757PubMedCrossRef

12.

Hall A, A’Hern R, Fallowfield L (1999) Are we using appropriate self-report questionnaires for detecting anxiety and depression in women with early breast cancer? Eur J Cancer 35:79–85PubMedCrossRef

13.

Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18:893–908PubMed

14.

Hotopf M, Chidgey J, Addington-Hall J et al (2002) Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 16:81–97PubMedCrossRef

15.

Johnston M, Pollard B, Hennessey P (2000) Construct validation of the hospital anxiety and depression scale with clinical population. J Psychosom Res 48:579–584PubMedCrossRef

16.

Kearns NP, Cruickshank CA, McGuigan KJ et al (1982) A comparison of depression rating scales. Br J Psychiatry 141:45–49PubMed

17.

Le Fevre P, Devereux J, Smith S (1999) Screening for psychiatric illness in the palliative care inpatient setting: a comparison between the Hospital Anxiety and Depression Scale and the General Health Questionnaire-12. Palliat Med 13:399–407PubMedCrossRef

18.

Lloyd-Williams M, Freidman T, Rudd N (2000) Criterion validation of the Edinburgh postnatal depression scale as a screening tool for depression in patients with advanced metastatic cancer. J Pain Symptom Manage 20:259–265PubMedCrossRef

19.

Mazumdar S, Lui KS, Houck PR, Reynolds CF 3rd (1999) Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values. J Psychiatr Res 33:87–95PubMedCrossRef

20.

McDonald MY, Passik SD, Dugan W (1999) Nurses’ recognition of depression in their patients with cancer. Oncol Nurs Forum 26:593–599PubMed

21.

Middelboe T, Ovesen L, Mortensen EL et al (1994) Depressive symptoms in cancer patients undergoing chemotherapy: a psychometric analysis. Psychother Psychosom 61:171–177PubMedCrossRef

22.

Montazeri A, Milroy R, Hole D et al (1998) Anxiety and depression in patients with lung cancer before and after diagnosis: findings from a population in Glasgow, Scotland. J Epidemiol Community Health 52:203–204PubMed

23.

Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389PubMed

24.

Moorey S, Greer S, Watson M et al (1991) The factor structure and factor stability of the hospital anxiety and depression scale in patients with cancer. Br J Psychiatry 158:255–259PubMedCrossRef

25.

Muller MJ, Himmerich H, Kienzle B et al (2003) Differentiating moderate and severe depression using the Montgomery–Asberg depression rating scale (MADRS). J Affect Disord 77:255–260PubMedCrossRef

26.

Mykletun A, Stordal E, Dahl AA (2001) Hospital Anxiety and Depression (HAD) scale: factor structure, item analyses and internal consistency in a large population. Br J Psychiatry 179:540–544PubMedCrossRef

27.

Passik SD, Kirsh KL, Donaghy KB et al (2001) An attempt to employ the Zung Self-Rating Depression Scale as a “lab test” to trigger follow-up in ambulatory oncology clinics: criterion validity and detection. J Pain Symptom Manage 21:273–281PubMedCrossRef

28.

Patrick DL, Ferketich SL, Frame PS et al (2004) National Institute of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15–17, 2002. J Natl Cancer Inst Monogr 32:9–16PubMed

29.

Schafer JL (1999) Multiple imputation: a primer. Stat Methods Med Res 8:3–15PubMedCrossRef

30.

Sharpe M, Strong V, Allen K et al (2004) Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 90:314–320PubMedCrossRef

31.

Skarstein J, Aass N, Fossa SD et al (2000) Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res 49:27–34PubMedCrossRef

32.

Snaith RP, Harrop FM, Newby DA et al (1986) Grade scores of the Montgomery–Asberg Depression and Clinical Anxiety Scales. Br J Psychiatry 148:599–601PubMedCrossRef

33.

Snaith RP, Taylor CM (1985) Rating scales for depression and anxiety: a current perspective. Br J Clin Pharmacol 19:175–200

34.

Littell RC, Milliken GA, Stroup WW et al (2006) SAS for mixed models, 2nd edn. SAS Institute, Cary, NC, USA

35.

Trask PC (2004) Assessment of depression in cancer patients. J Natl Cancer Inst Monogr 32:80–92PubMedCrossRef

36.

Uchitomi Y, Mikati I, Kugaya A et al (2000) Depression after successful treatment for nonsmall cell lung cancer. Cancer 89:1172–1179PubMedCrossRef

37.

Yung YC (2000) Multiple imputations for missing data: concepts and new development. SUGI Paper. SAS Institute, Cary, NC, USA, pp 267–325

38.

Zabora J, BrintzenhofeSzoc K, Curbow B et al (2001) The prevalence of psychological distress by cancer site. Psychooncology 1:19–28CrossRef

39.

Zimmerman M, Chelminski I, Pasternak M (2004) A review of studies of the Montgomery–Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol 19:1–7PubMedCrossRef

40.

Zimmerman M, Posternak MA, Chelminski I (2004) Derivation of a definition of remission on the Montgomery–Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 38:577–582PubMedCrossRef

Title: Screening for depressive symptoms in patients with unresectable lung cancer
Authors: S. Néron
J. A. Correa
E. Dajczman
G. Kasymjanova
H. Kreisman
D. Small
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 10/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0225-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Material and methods

Results

Clinical implication and conclusion

Please log in to get access to this content

Other articles of this Issue 10/2007

Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter

A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation

The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline

In response to the article “The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline” (Bolderston et al. 2006)

A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy

Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer